Acrivon Therapeutics’ shares climb 14% on plans to present cancer-test data

Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.

For more details: Read More